PCCI's 4th Annual May Roundtable
Life Science Success Stories
Monday, May 9, 2011
Time: 6.00PM: Networking; 7.00PM: Dinner
8.00PM: Roundtable and Discussion
Host: Pharmaceutical Consulting Consortium International Inc.
Location: Embassy Suites, Chesterbrook, Pennsylvania (directions)
Seating will be limited to 120 people; parking is free
The event will also be webcast. Those who cannot join the meeting can still participate. Webcast registration will be $30. A password will be given.
This May’s panel members will talk about how they started their companies, what challenges they faced, what they thought they did well, and what they think they could have done better. Could they have the same success in the present economy? How would they go about starting a company today and what challenges do they see as particularly daunting? What opportunities exist now that were not there when they took the reins? Early-stage companies, almost by definition, evolve; how do successful entrepreneurs deal with a moving target like that?
The Pharmaceutical Consortium International Inc. (PCCI) is a group of nearly 300 consultants, attorneys, investors, executives, etc. from all walks of Pharma and Life Sciences. Members and guests meet once a month to help promising early-stage life science companies get to the next level. Once a year, the group meets to look at industry wide issues, such as today’s success stories.
Jane Hollingsworth, CEO Nupathe
James Sapirstein, Founder Tobira Pharmaceuticals
Nick Spring, President and CEO Rainbow Pharmaceuticals
Stephen Tullman, Executive Chairman Vicept Pharmaceuticals
Moderated by: Kate Shay, Partner Duane Morris
6:00 - Networking
7:00 - Dinner
8:00 - Roundtable and Discussion
<Top of the page>
Partner, Duane Morris LLP
Kathleen M. Shay, a partner at the law firm of Duane Morris LLP, is a corporate and securities lawyer who focuses her practice on the life science industry. She represents public and private biopharmaceutical and medical device companies, healthcare services companies, venture capital funds and other investors in the life science and healthcare industries, academic and research institutions, and life science industry collaborators and service providers.
Kate represents both established and emerging businesses in a wide range of legal transactions and issues, including debt and equity financings, structuring transactions, licenses and strategic relationships, mergers and acquisitions, governance matters, and employment and compensation issues.
Kate is a longstanding member of her firm’s Partners Board and served as the Chair of her firm’s Corporate Practice Group from 1996 to 2005. She also serves on the Board of Directors of the Philadelphia Alliance for Capital and Technologies and the Board of Consultors of Villanova Law School. Kate recently completed her second term as director of the Philadelphia Chapter of the Association for Corporate Growth and as a trustee of the Academy of Notre Dame de Namur. She is an Advisory Board member and former director of the Alliance of Women Entrepreneurs (previously Women’s Investment Network) and has served as AWE’s counsel since its inception. Kate previously served as the Chair of the Executive Committee of the Business Law Section of the Philadelphia Bar Association and is a past-Chair of the Securities Regulation Committee. She is also an active member of the Pennsylvania Biotechnology Association.
Kate received her B.A. from Villanova University and her J.D. from Villanova University School of Law, where she served as Editor-in-Chief of The Villanova Law Review.
Duane Morris LLP, among the one hundred largest law firms in the nation, is a full service firm of approximately 750 lawyers. In addition, Duane Morris affiliates have approximately 40 professionals engaged in non-legal service businesses. The firm represents clients across the United States and around the world through its offices in the United States, London and Asia, and relationships with two international networks of independent law firms.
Chief Executive Officer, NuPathe Inc.
Jane is co-founder and CEO of NuPathe Inc., a Philadelphia area specialty pharmaceutical company, focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe has quickly advanced a product pipeline of treatments to address critical patient needs. The company's most advanced product candidate is its sumatriptan transdermal patch for the treatment of migraine, currently under review by the FDA. Nupathe is also developing treatments for Parkinson's disease and schizophrenia and bipolar disorder.
Prior to founding NuPathe, Jane was the co-founder and Executive Vice President of Auxilium Pharmaceuticals, a specialty pharmaceutical company focused on urology and novel treatments for unmet medical needs. Within five years of its founding, Auxilium successfully developed, obtained FDA approval for, and launched its first product; and completed an initial public offering. Prior to founding and launching two successful specialty pharmaceutical companies, Ms. Hollingsworth was Vice President, Secretary & General Counsel of IBAH, Inc., a publicly-traded, multinational CRO that developed and obtained regulatory approval for many pharmaceutical and biologic products. Before joining IBAH, she was a commercial litigator at the Philadelphia law firm of Montgomery, McCracken, Walker & Rhoads and served as law clerk to the Honorable Jane R. Roth of the United States District Court for the District of Delaware.
Ms. Hollingsworth is one of the leaders of the biotech community in Philadelphia and is active in fostering the growth of entrepreneurship in biotech and other industries.
Founder, Tobira Therapeutics, Inc.
James was the President and CEO of Tobira Therapeutics, a NJ based biopharmaceutical company, developing novel compounds for HIV/AIDS and inflammatory diseases. He brings over 27 years of pharmaceutical experience, 21 years of management experience and 22 years of Infectious Disease specialty focus to Tobira.
Prior to Tobira, James’s most recent role was as the Executive Vice President of the Metabolic and Endocrinology Business Unit at Serono, Inc., where he gained his experience working with biological products. He joined Serono in 2002 with the responsibility for turning around a failing HIV/AIDS franchise, while growing a struggling pediatric growth hormone business. In his role as Business Unit Head, James built and led a team of over 100 people that commercialized Serostim®, Saizen® and Zorbtive® in the United States.
Prior to joining Serono, James worked at Gilead Sciences where he was responsible for the global launch of Gilead’s flagship product, Viread®. He joined Gilead after working at Bristol-Myers Squibb where he served as the head of its International HIV business as well working in its Infectious Disease marketing teams. He launched several products at BMS, including Videx EC®, Zerit®, Tequin®, Maxipime® and Cefzil®. In addition, he helped launch SENTRY, BMS’ worldwide Surveillance program for Infectious Diseases with Ron Jones of the University of Iowa. James was also instrumental in initiating BMS’ 100 million dollar “Secure the Future” program which provided funding for clinical trials and educational development throughout Southern Africa.
Prior to BMS, James spent almost 10 years with Hoffmann- LaRoche in a variety of capacities ranging from marketing and sales positions to international posts. He was involved with several product launches at Roche such as Ceftin®, Hivid®, Invirase®, Rocephin®, Tasmar® and Toradol®. James started his career at Eli Lilly in sales right after attaining his pharmacy degree. He was involved in the promotion of Lilly’s antibiotic line, specifically their hospital products.
In addition to his pharmacy degree from Rutgers University and Ernest Mario School of Pharmacy, he holds a Master’s Degree in Business Administration from Farleigh Dickinson University. He has also worked in numerous other specialties outside of Infectious Diseases, including Dermatology, Neurology, Anesthesia, Oncology, Cardiology, Gastroenterology and Pain Management.
Co-Founder, President and CEO, Rainbow Pharmaceuticals
Nick Spring is a highly experienced entrepreneur with an excellent track record of success in the global pharmaceutical business. He has lived and worked in Europe, Australia/NZ as well as the USA. Before co-founding Rainbow Pharmaceuticals Inc, Nick founded Topaz Pharmaceuticals Inc., where he still serves on the Board.
As Founder of Topaz Pharmaceuticals Inc., he drove the company from an idea/business plan, via four rounds of funding from a pre-clinical situation, through FDA Phase I, II, IIb and III to NDA filing. The company was recognized by the Eastern Technology Council Awards as a "Company to Watch" in 2007 and was runner up as "Emerging Life Sciences Company of the Year" in 2009.
Nick has nearly 30 years of pharmaceutical and consumer marketing experience. He has enjoyed a diverse career at Merck & Co., Smith and Nephew LLC, and Scott Paper Inc.
Mr. Spring is an adjunct Associate Professor at the Mayes Business School, University of Sciences in Philadelphia, PA. He is also a Fellow of the Zoological Society of London.
Executive Chairman, Vicept Therapeutics
Vicept Therapeutics was established in 2009 to develop new treatments for Rosacea. Previously, Steve was co-founder, President and CEO of Ception Therapeutics, a biologics company acquired by Cephalon in April 2010. Previous to the formation of Ception, he co-founded Trigenesis Therapeutics, a dermatology company, sold in 2004 to Reddy Laboratories.
Mr. Tullman is also a co-founder and Director of Cutix Pharmaceuticals, a privately held sun care company selling PreSun®, a leading specialty sunscreen product line. He was also a Board Director for Euromed, a wound care specialty company.
Mr. Tullman has 22+ years of pharmaceutical industry experience. He has a proven ability to build strong relationships in the complex arena of pharmaceutical R&D. His leadership style is to motivate with trust and empowerment. These skills, combined with his innovative and entrepreneurial thinking and ability to champion change, has consistently resulted in rapid value creation.
A reoccurring theme of over the years has been insight and drive for business development transactions that have resulted in the establishment and progression of several entrepreneurial and strategic ventures. Steve started his career in the pharmaceutical industry at SmithKline Beecham (now GSK). There he accumulated 14 years of broad industry experience in finance, sales, marketing, and R&D. He has worked overseas, living in both the UK and Southeast Asia and has many years of overall global commercial development responsibility.
Steve has received many awards, most recently he was honored with the Walter M. Aikman Entrepreneur of the Year Award, June 2010.
<Top of the page>